 <h1>Spravato Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>esketamine</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about esketamine. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Spravato.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to esketamine: nasal spray</i></p><h3>Warning</h3><p class="blackboxWarning-title">Nasal route (Spray)</p><p>Warning: Sedation; Dissociation; Abuse and Misuse; and Suicidal Thoughts and BehaviorsRisk for sedation and dissociation after administration. Monitor patients for at least 2 hours after administration.Potential for abuse and misuse. Consider the risks and benefits of prescribing esketamine prior to using in patients at higher risk of abuse. Monitor patients for signs and symptoms of abuse and misuse.Esketamine is only available through a restricted program call the SPRAVATO(TM) REMS.Increased risk of suicidal thoughts and behaviors in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors. Esketamine is not approved for use in pediatric patients.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, esketamine (the active ingredient contained in Spravato) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking esketamine:</p><p>
<i>More common</i>
</p><ul>
<li>Anxiety</li>
<li>blurred vision</li>
<li>confusion about identity, time, and place</li>
<li>dizziness</li>
<li>drowsiness</li>
<li>feeling of constant movement of self or surroundings</li>
<li>feeling of unreality</li>
<li>headache</li>
<li>lightheadedness</li>
<li>nervousness</li>
<li>pounding in the ears</li>
<li>relaxed and calm feeling</li>
<li>sensation of spinning</li>
<li>sense of detachment from self or body</li>
<li>sleepiness</li>
<li>slow or fast heartbeat</li>
<li>unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Changes in patterns and rhythms of speech</li>
<li>excitement</li>
<li>false or unusual sense of well-being</li>
<li>fast, pounding, or irregular heartbeat or pulse</li>
<li>feeling abnormal or drunk</li>
<li>frequent daytime urination</li>
<li>nightmares or unusually vivid dreams</li>
<li>slurred speech</li>
<li>tremor</li>
<li>trouble in speaking</li>
<li>urinating small amounts of urine at a time</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Changes in behavior</li>
<li>chest pain or discomfort</li>
<li>discouragement</li>
<li>fast or pounding heartbeat</li>
<li>feeling sad or empty</li>
<li>irritability</li>
<li>lack of appetite</li>
<li>loss of interest or pleasure</li>
<li>sweating</li>
<li>thoughts of killing oneself</li>
<li>trouble concentrating</li>
<li>trouble sleeping</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of esketamine may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings</li>
<li>change in or loss of taste</li>
<li>diarrhea</li>
<li>nasal itching, burning, or irritation</li>
<li>nausea</li>
<li>throat irritation</li>
<li>vomiting</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Constipation</li>
<li>dry mouth</li>
<li>mouth or throat pain</li>
</ul><p>
<!-- end nasal spray --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to esketamine: nasal spray</i></p><h3>General</h3><p>Nasal:</p>
<p>The most commonly reported side effects included dissociation, sedation, nausea, and dizziness.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Dissociation (e.g., depersonalization, derealization, perceptual changed [distortion of time, place, and illusions]) occurred in up to 75% of patients 65 years and older given this drug PLUS oral antidepressant therapy.<sup>[Ref]</sup></p><p>Nasal:</p>
<p><b>Very common</b> (10% or more): Dissociation (up to 75%), anxiety (up to 13%)</p>
<p><b>Common</b> (1% to 10%): Agitation, altered time perception, anxiety, derealization, euphoric mood, hallucination, illusion, insomnia, irritability, panic attack, visual hallucination</p>
<p><b>Uncommon</b> (0.1% to 1%): Suicidal ideation</p>
<p><b>Frequency not reported</b>: Anticipatory anxiety, auditory hallucination, delusional perception, depersonalization/derealization disorder, fear, nervousness, tension</p>
<p></p>
<p>Parenteral:</p>
<p><b>Common</b> (1% to 10%): Nightmares, vivid dreams</p>
<p><b>Frequency not reported</b>: Anxiety, disorientation, dysphoria, hallucinations<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Sedation occurred in up to 61% of patients younger than 65 years given 84 mg of this drug intranasally PLUS oral antidepressant therapy.</p>
<p></p>
<p>Clonic and tonic movements resembling convulsions occurred as a result of increased muscle tonus in patients given parenteral formulations.</p>
<p></p>
<p>Increased brain pressure occurred in patients given parenteral formulations who were not under adequate ventilation.<sup>[Ref]</sup></p><p>Nasal:</p>
<p><b>Very common</b> (10% or more): Sedation (up to 61%), dizziness (up to 30%), headache (up to 24%), vertigo (up to 23%), dysgeusia (up to 19%), hypoesthesia (up to 18%), somnolence (up to 18%), lethargy (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Dysarthria, mental impairment, paresthesia, tremor</p>
<p><b>Frequency not reported</b>: Altered state of consciousness, cognitive impairment, dizziness exertional, dizziness postural, dysesthesia, hypersomnia, hypogeusia, impaired ability to drive/operate machinery, procedural dizziness, sinus headache, slow speech, speech disorder, vertigo positional</p>
<p></p>
<p>Parenteral:</p>
<p><b>Common</b> (1% to 10%): Dizziness, increased brain pressure, motor restlessness</p>
<p><b>Uncommon</b> (0.1% to 1%): Clonic movements, convulsions, nystagmus, tonic movements<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Nausea occurred in 32% of patients given 84 mg intranasal doses and 27% of patients given 56 mg intranasal doses.  Severe nausea was reported in 3% of patients given 84 mg intranasal doses.</p>
<p></p>
<p>Vomiting occurred in 6% of patients given 84 mg intranasal doses and 12% of patients given 56 mg intranasal doses.  Severe nausea was reported in 3% of patients given 84 mg intranasal doses.<sup>[Ref]</sup></p><p>Nasal:</p>
<p><b>Very common</b> (10% or more): Nausea (up to 32%), vomiting (up to 12%)</p>
<p><b>Common</b> (1% to 10%): Constipation, diarrhea, dry mouth, oral hypesthesia, severe nausea, severe vomiting</p>
<p><b>Uncommon</b> (0.1% to 1%): Salivary hypersecretion</p>
<p><b>Frequency not reported</b>: Hypoesthesia teeth, oral dysesthesia, paresthesia oral</p>
<p></p>
<p>Parenteral:</p>
<p><b>Common</b> (1% to 10%): Increased salivation, nausea, vomiting<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>At least 25 mmHg increase in diastolic blood pressure occurred in up to 14% of patients 65 years and older given this drug PLUS oral antidepressant therapy.</p>
<p></p>
<p>At least 40 mmHg increase in systolic blood pressure occurred in up to 17% of patients 65 years and older given this drug PLUS oral antidepressant therapy.</p>
<p></p>
<p>Blood pressure and heart rate increases of 20% from baseline occurred in patients given parenteral formulations.</p>
<p></p>
<p>Hypotension in parenteral formulations occurred, especially with circulatory shock.  Patients with shock developed further reductions in blood pressure.</p>
<p></p>
<p>Increased vascular resistance in pulmonary circulation occurred with parenteral formulations, especially in those with restricted coronary reserve.<sup>[Ref]</sup></p><p>Nasal:</p>
<p><b>Very common</b> (10% or more): At least 40 mmHg increase in systolic blood pressure (up to 17%), at least 25 mmHg increase in diastolic blood pressure (up to 14%)</p>
<p><b>Common</b> (1% to 10%): Blood pressure increased, diastolic blood pressure at least 110 mmHg, systolic blood pressure at least 180 mmHg, tachycardia</p>
<p><b>Frequency not reported</b>: Blood pressure diastolic increased, blood pressure systolic increased, extrasystoles, heart rate increased, hypertension</p>
<p></p>
<p>Parenteral:</p>
<p><b>Common</b> (1% to 10%): Blood pressure increase, heart rate increase, increased vascular resistance in pulmonary circulation, temporary tachycardia</p>
<p><b>Rare</b> (0.01% to 0.1%): Arrythmia, bradycardia, hypotension</p>
<p><b>Very rare</b> (less than 0.01%): Severe hypotension</p>
<p><b>Frequency not reported</b>: Circulatory shock<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Dose and rate of injection were correlated with the risk of respiratory depression.<sup>[Ref]</sup></p><p>Nasal:</p>
<p><b>Common</b> (1% to 10%): Nasal crusting, nasal discomfort, nasal dryness, nasal pruritus, oropharyngeal pain, pharyngeal paresthesia, throat irritation</p>
<p></p>
<p>Parenteral:</p>
<p><b>Common</b> (1% to 10%): Laryngospasm, temporary respiratory depression<sup>[Ref]</sup></p><h3>Other</h3><p>Nasal:</p>
<p><b>Common</b> (1% to 10%): Feeling abnormal, feeling drunk, feeling of body temperature change, hyperacusis, tinnitus</p>
<p><b>Frequency not reported</b>: Embryofetal toxicity, fatigue, feeling cold, feeling hot, feeling jittery</p>
<p></p>
<p>Parenteral:</p>
<p><b>Common</b> (1% to 10%): Increased mucus secretion, recovery reactions<sup>[Ref]</sup></p><p>Increased mucus secretion occurred with parenteral formulations, especially in those with restricted coronary reserve.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Nasal:</p>
<p><b>Common</b> (1% to 10%): Dysuria, micturition urgency, pollakiuria</p>
<p><b>Frequency not reported</b>: Interstitial cystitis, ulcerative cystitis<sup>[Ref]</sup></p><h3>Ocular</h3><p>Nasal:</p>
<p><b>Common</b> (1% to 10%): Blurred vision</p>
<p><b>Frequency not reported</b>: Diplopia, ocular discomfort, photophobia, visual impairment</p>
<p></p>
<p>Parenteral:</p>
<p><b>Common</b> (1% to 10%): Blurred vision</p>
<p><b>Uncommon</b> (0.1% to 1%): Diplopia, increased intraocular pressure<sup>[Ref]</sup></p><h3>Local</h3><p>Parenteral:</p>
<p><b>Common</b> (1% to 10%): Hyperreflexia, laryngeal spasms</p>
<p><b>Uncommon</b> (0.1% to 1%): Injection site erythema, injection site pain<sup>[Ref]</sup></p><p>Hyperreflexia and laryngospasm may occur in parenteral formulations with upper respiratory tract diagnostic and/or therapeutic interventions, especially in pediatric patients; muscle relaxation with adequate ventilation may be needed in procedures involving the bronchial tree, larynx, and/or pharynx.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Nasal:</p>
<p><b>Common</b> (1% to 10%): Hyperhidrosis</p>
<p></p>
<p>Parenteral:</p>
<p><b>Uncommon</b> (0.1% to 1%): Exanthema, morbilliform rash<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Increased muscle tone occurred in patients given parenteral formulations who were not under adequate ventilation.<sup>[Ref]</sup></p><p>Nasal:</p>
<p><b>Uncommon</b> (0.1% to 1%): Muscular weakness</p>
<p></p>
<p>Parenteral:</p>
<p><b>Common</b> (1% to 10%): Increased muscle tone<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Parenteral:</p>
<p><b>Rare</b> (0.01% to 0.1%): Anaphylaxis</p>
<p><b>Very rare</b> (less than 0.01%): Anaphylactoid reactions, hypersensitivity reactions<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Drug-induced liver injury occurred in extended use (e.g., greater than 3 days) and/or with abuse.<sup>[Ref]</sup></p><p>Parenteral:</p>
<p><b>Frequency not reported</b>: Abnormal liver function tests, drug-induced liver injury<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Parenteral:</p>
<p><b>Common</b> (1% to 10%): Increased oxygen consumption<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. "Product Information. Spravato (esketamine)." Janssen Pharmaceuticals, Titusville, NJ. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>Is Spravato (esketamine) a controlled substance?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Spravato (esketamine)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>46 Reviews</li>
<li>Drug class: miscellaneous antidepressants</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Spravato &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Major Depressive Disorder</li>
<li>Depression</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to esketamine: nasal spray</i></p><h3>General</h3><p>Nasal:</p><p>The most commonly reported side effects included dissociation, sedation, nausea, and dizziness.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Dissociation (e.g., depersonalization, derealization, perceptual changed [distortion of time, place, and illusions]) occurred in up to 75% of patients 65 years and older given this drug PLUS oral antidepressant therapy.<sup>[Ref]</sup></p><p>Nasal:</p><p><b>Very common</b> (10% or more): Dissociation (up to 75%), anxiety (up to 13%)</p><p><b>Common</b> (1% to 10%): Agitation, altered time perception, anxiety, derealization, euphoric mood, hallucination, illusion, insomnia, irritability, panic attack, visual hallucination</p><p><b>Uncommon</b> (0.1% to 1%): Suicidal ideation</p><p><b>Frequency not reported</b>: Anticipatory anxiety, auditory hallucination, delusional perception, depersonalization/derealization disorder, fear, nervousness, tension</p><p></p><p>Parenteral:</p><p><b>Common</b> (1% to 10%): Nightmares, vivid dreams</p><p><b>Frequency not reported</b>: Anxiety, disorientation, dysphoria, hallucinations<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Sedation occurred in up to 61% of patients younger than 65 years given 84 mg of this drug intranasally PLUS oral antidepressant therapy.</p><p></p><p>Clonic and tonic movements resembling convulsions occurred as a result of increased muscle tonus in patients given parenteral formulations.</p><p></p><p>Increased brain pressure occurred in patients given parenteral formulations who were not under adequate ventilation.<sup>[Ref]</sup></p><p>Nasal:</p><p><b>Very common</b> (10% or more): Sedation (up to 61%), dizziness (up to 30%), headache (up to 24%), vertigo (up to 23%), dysgeusia (up to 19%), hypoesthesia (up to 18%), somnolence (up to 18%), lethargy (up to 11%)</p><p><b>Common</b> (1% to 10%): Dysarthria, mental impairment, paresthesia, tremor</p><p><b>Frequency not reported</b>: Altered state of consciousness, cognitive impairment, dizziness exertional, dizziness postural, dysesthesia, hypersomnia, hypogeusia, impaired ability to drive/operate machinery, procedural dizziness, sinus headache, slow speech, speech disorder, vertigo positional</p><p></p><p>Parenteral:</p><p><b>Common</b> (1% to 10%): Dizziness, increased brain pressure, motor restlessness</p><p><b>Uncommon</b> (0.1% to 1%): Clonic movements, convulsions, nystagmus, tonic movements<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Nausea occurred in 32% of patients given 84 mg intranasal doses and 27% of patients given 56 mg intranasal doses.  Severe nausea was reported in 3% of patients given 84 mg intranasal doses.</p><p></p><p>Vomiting occurred in 6% of patients given 84 mg intranasal doses and 12% of patients given 56 mg intranasal doses.  Severe nausea was reported in 3% of patients given 84 mg intranasal doses.<sup>[Ref]</sup></p><p>Nasal:</p><p><b>Very common</b> (10% or more): Nausea (up to 32%), vomiting (up to 12%)</p><p><b>Common</b> (1% to 10%): Constipation, diarrhea, dry mouth, oral hypesthesia, severe nausea, severe vomiting</p><p><b>Uncommon</b> (0.1% to 1%): Salivary hypersecretion</p><p><b>Frequency not reported</b>: Hypoesthesia teeth, oral dysesthesia, paresthesia oral</p><p></p><p>Parenteral:</p><p><b>Common</b> (1% to 10%): Increased salivation, nausea, vomiting<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>At least 25 mmHg increase in diastolic blood pressure occurred in up to 14% of patients 65 years and older given this drug PLUS oral antidepressant therapy.</p><p></p><p>At least 40 mmHg increase in systolic blood pressure occurred in up to 17% of patients 65 years and older given this drug PLUS oral antidepressant therapy.</p><p></p><p>Blood pressure and heart rate increases of 20% from baseline occurred in patients given parenteral formulations.</p><p></p><p>Hypotension in parenteral formulations occurred, especially with circulatory shock.  Patients with shock developed further reductions in blood pressure.</p><p></p><p>Increased vascular resistance in pulmonary circulation occurred with parenteral formulations, especially in those with restricted coronary reserve.<sup>[Ref]</sup></p><p>Nasal:</p><p><b>Very common</b> (10% or more): At least 40 mmHg increase in systolic blood pressure (up to 17%), at least 25 mmHg increase in diastolic blood pressure (up to 14%)</p><p><b>Common</b> (1% to 10%): Blood pressure increased, diastolic blood pressure at least 110 mmHg, systolic blood pressure at least 180 mmHg, tachycardia</p><p><b>Frequency not reported</b>: Blood pressure diastolic increased, blood pressure systolic increased, extrasystoles, heart rate increased, hypertension</p><p></p><p>Parenteral:</p><p><b>Common</b> (1% to 10%): Blood pressure increase, heart rate increase, increased vascular resistance in pulmonary circulation, temporary tachycardia</p><p><b>Rare</b> (0.01% to 0.1%): Arrythmia, bradycardia, hypotension</p><p><b>Very rare</b> (less than 0.01%): Severe hypotension</p><p><b>Frequency not reported</b>: Circulatory shock<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Dose and rate of injection were correlated with the risk of respiratory depression.<sup>[Ref]</sup></p><p>Nasal:</p><p><b>Common</b> (1% to 10%): Nasal crusting, nasal discomfort, nasal dryness, nasal pruritus, oropharyngeal pain, pharyngeal paresthesia, throat irritation</p><p></p><p>Parenteral:</p><p><b>Common</b> (1% to 10%): Laryngospasm, temporary respiratory depression<sup>[Ref]</sup></p><h3>Other</h3><p>Nasal:</p><p><b>Common</b> (1% to 10%): Feeling abnormal, feeling drunk, feeling of body temperature change, hyperacusis, tinnitus</p><p><b>Frequency not reported</b>: Embryofetal toxicity, fatigue, feeling cold, feeling hot, feeling jittery</p><p></p><p>Parenteral:</p><p><b>Common</b> (1% to 10%): Increased mucus secretion, recovery reactions<sup>[Ref]</sup></p><p>Increased mucus secretion occurred with parenteral formulations, especially in those with restricted coronary reserve.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Nasal:</p><p><b>Common</b> (1% to 10%): Dysuria, micturition urgency, pollakiuria</p><p><b>Frequency not reported</b>: Interstitial cystitis, ulcerative cystitis<sup>[Ref]</sup></p><h3>Ocular</h3><p>Nasal:</p><p><b>Common</b> (1% to 10%): Blurred vision</p><p><b>Frequency not reported</b>: Diplopia, ocular discomfort, photophobia, visual impairment</p><p></p><p>Parenteral:</p><p><b>Common</b> (1% to 10%): Blurred vision</p><p><b>Uncommon</b> (0.1% to 1%): Diplopia, increased intraocular pressure<sup>[Ref]</sup></p><h3>Local</h3><p>Parenteral:</p><p><b>Common</b> (1% to 10%): Hyperreflexia, laryngeal spasms</p><p><b>Uncommon</b> (0.1% to 1%): Injection site erythema, injection site pain<sup>[Ref]</sup></p><p>Hyperreflexia and laryngospasm may occur in parenteral formulations with upper respiratory tract diagnostic and/or therapeutic interventions, especially in pediatric patients; muscle relaxation with adequate ventilation may be needed in procedures involving the bronchial tree, larynx, and/or pharynx.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Nasal:</p><p><b>Common</b> (1% to 10%): Hyperhidrosis</p><p></p><p>Parenteral:</p><p><b>Uncommon</b> (0.1% to 1%): Exanthema, morbilliform rash<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Increased muscle tone occurred in patients given parenteral formulations who were not under adequate ventilation.<sup>[Ref]</sup></p><p>Nasal:</p><p><b>Uncommon</b> (0.1% to 1%): Muscular weakness</p><p></p><p>Parenteral:</p><p><b>Common</b> (1% to 10%): Increased muscle tone<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Parenteral:</p><p><b>Rare</b> (0.01% to 0.1%): Anaphylaxis</p><p><b>Very rare</b> (less than 0.01%): Anaphylactoid reactions, hypersensitivity reactions<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Drug-induced liver injury occurred in extended use (e.g., greater than 3 days) and/or with abuse.<sup>[Ref]</sup></p><p>Parenteral:</p><p><b>Frequency not reported</b>: Abnormal liver function tests, drug-induced liver injury<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Parenteral:</p><p><b>Common</b> (1% to 10%): Increased oxygen consumption<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. "Product Information. Spravato (esketamine)." Janssen Pharmaceuticals, Titusville, NJ. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>Is Spravato (esketamine) a controlled substance?</li>
</ul><h2>More about Spravato (esketamine)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>46 Reviews</li>
<li>Drug class: miscellaneous antidepressants</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Spravato &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Major Depressive Disorder</li>
<li>Depression</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>